Skip to content

Abivax

  • EN
  • FR
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
  • EN
  • FR

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

FierceBiotech

September 4, 2018

Abivax posts ulcerative colitis data, commits to phase 2b

MarketWatch

September 4, 2018

Abivax stock surges 9% on trial results for ulcerative colitis therapy

BioSpace

September 4, 2018

Abivax Bolstered by Positive Mid-Stage Results from Ulcerative Colitis Treatment

Drug Development Technology

July 20, 2018

Abivax completes dosing in ABX464-101 trial for UC

Draining HIV Viral Reservoirs: Abivax Prepares ABX464 Cure For Phase IIb

July 5, 2018

Draining HIV Viral Reservoirs: Abivax Prepares ABX464 Cure For Phase IIb

  • 1
  • 2
  • 3

References available upon request.

© 2025 All rights reserved by Abivax 06/2025 Privacy and Terms of Use
Consent Preferences
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn